CAPTRUST Financial Advisors’s Oragenics OGEN Stock Holding History

CAPTRUST Financial Advisors’s Portfolio OGEN Stock Details OGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-2	Closed	-$3K	–	4616
2021 Q1	$3K	Buy	+2	New	+$3.63K	﹤0.01%	3930

Other funds holding OGEN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SBF

Sara-Bay Financial Sarasota, Florida $375M AUM 56.53% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

CAPTRUST Financial Advisors's OGEN Position: Q2 2021 in Review

CAPTRUST Financial Advisors sold out of Oragenics (OGEN) in Q2 2021, closing a stake of 2 shares — an estimated $3K sold.

CAPTRUST Financial Advisors first reported a position in OGEN in Q1 2021 and held it in 1 quarter. The position peaked at $3K in Q1 2021. 17 funds tracked by Wall St. Rank hold OGEN as of Q2 2021.

CAPTRUST Financial Advisors reported no remaining Oragenics position as of Q2 2021 after selling out during the quarter.
CAPTRUST Financial Advisors sold 2 Oragenics shares in Q2 2021, an estimated $3K.
CAPTRUST Financial Advisors first reported a position in Oragenics in Q1 2021 and held it in 1 quarter.
CAPTRUST Financial Advisors's Oragenics position peaked at $3K in Q1 2021.
17 funds tracked by Wall St. Rank held Oragenics as of Q2 2021.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.